Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2004 1
2010 1
2011 2
2012 1
2013 1
2014 1
2015 2
2016 3
2017 5
2018 3
2019 8
2020 7
2021 6
2022 6
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Leiomyosarcoma: Current Clinical Management and Future Horizons.
Devaud N, Vornicova O, Abdul Razak AR, Khalili K, Demicco EG, Mitric C, Bernardini MQ, Gladdy RA. Devaud N, et al. Among authors: abdul razak ar. Surg Oncol Clin N Am. 2022 Jul;31(3):527-546. doi: 10.1016/j.soc.2022.03.011. Surg Oncol Clin N Am. 2022. PMID: 35715148 Review.
The Future of Clinical Trial Design in Oncology.
Spreafico A, Hansen AR, Abdul Razak AR, Bedard PL, Siu LL. Spreafico A, et al. Among authors: abdul razak ar. Cancer Discov. 2021 Apr;11(4):822-837. doi: 10.1158/2159-8290.CD-20-1301. Cancer Discov. 2021. PMID: 33811119 Free PMC article. Review.
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR, Bauer S, Suarez C, Lin CC, Quek R, Hütter-Krönke ML, Cubedo R, Ferretti S, Guerreiro N, Jullion A, Orlando EJ, Clementi G, Sand Dejmek J, Halilovic E, Fabre C, Blay JY, Italiano A. Abdul Razak AR, et al. Clin Cancer Res. 2022 Mar 15;28(6):1087-1097. doi: 10.1158/1078-0432.CCR-21-1291. Clin Cancer Res. 2022. PMID: 34921024 Clinical Trial.
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.
Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Tap WD, et al. Among authors: abdul razak ar. JAMA. 2020 Apr 7;323(13):1266-1276. doi: 10.1001/jama.2020.1707. JAMA. 2020. PMID: 32259228 Free PMC article. Clinical Trial.
Early phase clinical trials to identify optimal dosing and safety.
Cook N, Hansen AR, Siu LL, Abdul Razak AR. Cook N, et al. Among authors: abdul razak ar. Mol Oncol. 2015 May;9(5):997-1007. doi: 10.1016/j.molonc.2014.07.025. Epub 2014 Aug 14. Mol Oncol. 2015. PMID: 25160636 Free PMC article. Review.
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, Noto P, Tarkar A, Garrido-Laguna I, Calvo E, Rodón J, Tran B, O'Dwyer PJ, Cuker A, Abdul Razak AR. El-Khoueiry AB, et al. Among authors: abdul razak ar. Br J Cancer. 2023 Aug;129(2):309-317. doi: 10.1038/s41416-023-02276-0. Epub 2023 May 26. Br J Cancer. 2023. PMID: 37237172 Free PMC article. Clinical Trial.
Early changes in tumor-naive cell-free methylomes and fragmentomes predict outcomes in pembrolizumab-treated solid tumors.
Stutheit-Zhao EY, Sanz-Garcia E, Liu ZA, Wong D, Marsh K, Abdul Razak AR, Spreafico A, Bedard PL, Hansen AR, Lheureux S, Torti D, Lam B, Yang SYC, Burgener J, Luo P, Zeng Y, Cheng N, Awadalla P, Bratman SV, Ohashi PS, Pugh TJ, Siu LL. Stutheit-Zhao EY, et al. Among authors: abdul razak ar. Cancer Discov. 2024 Feb 23. doi: 10.1158/2159-8290.CD-23-1060. Online ahead of print. Cancer Discov. 2024. PMID: 38393391
49 results